Recombinant Human TRANCE/RANK L/TNFSF11 Protein | R&D Systems 390-TN product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

catalog :

390-TN

quantity :

10 ug

price :

329 USD

citations: 33

Reference
Xue J, Xu L, Zhu H, Bai M, Li X, Zhao Z, et al. CD14+CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK. Arthritis Res Ther. 2020;22:221 pubmed publisher
Brunner J, Vulliard L, Hofmann M, Kieler M, Lercher A, Vogel A, et al. Environmental arginine controls multinuclear giant cell metabolism and formation. Nat Commun. 2020;11:431 pubmed publisher
Li K, Chen S, Cai P, Chen K, Li L, Yang X, et al. MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation. Mol Cell Probes. 2020;49:101479 pubmed publisher
Lee K, Kim K, Kim B, Won J, Min H, Lee D, et al. Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis. Arthritis Res Ther. 2019;21:283 pubmed publisher
Zoi I, Karamouzis M, Xingi E, Sarantis P, Thomaidou D, Lembessis P, et al. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas. Breast Cancer Res. 2019;21:132 pubmed publisher
Yeh I, Chen S, Yen M, Wu Y, Hung C, Kuo P. 6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic Potential. Nutrients. 2019;11: pubmed publisher
Collins F, Stone M, Turton J, McCabe L, Wang E, Williams A. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels. BMC Musculoskelet Disord. 2019;20:326 pubmed publisher
Löfvall H, Katri A, Dąbrowska A, Karsdal M, Luo Y, He Y, et al. GPDPLQ1237-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro. Sci Rep. 2019;9:3050 pubmed publisher
Møller A, Füchtbauer E, Brüel A, Andersen T, Borggaard X, Pavlos N, et al. Septins are critical regulators of osteoclastic bone resorption. Sci Rep. 2018;8:13016 pubmed publisher
Kjelgaard Petersen C, Platt A, Braddock M, Jenkins M, Musa K, Graham E, et al. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70:1419-1428 pubmed publisher
Davenport C, Harper E, Rochfort K, Forde H, Smith D, Cummins P. RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain. J Vasc Res. 2018;55:111-123 pubmed publisher
Clarke A, Poulton L, Shim D, Mabon D, Butt D, Pollard M, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10:664-677 pubmed publisher
Hussein H, Boyaka P, Dulin J, Russell D, Smanik L, Azab M, et al. Cathepsin K Localizes to Equine Bone In Vivo and Inhibits Bone Marrow Stem and Progenitor Cells Differentiation In Vitro. J Stem Cells Regen Med. 2017;13:45-53 pubmed
Sućur A, Jajic Z, Artuković M, Matijasevic M, Anic B, Flegar D, et al. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells. Arthritis Res Ther. 2017;19:142 pubmed publisher
Lu B, Jiao Y, Wang Y, Dong J, Wei M, Cui B, et al. A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis. Exp Mol Med. 2017;49:e336 pubmed publisher
Chinetti Gbaguidi G, Daoudi M, Rosa M, Vinod M, Louvet L, Copin C, et al. Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity. Circ Res. 2017;121:19-30 pubmed publisher
Kamalakar A, Washam C, Akel N, Allen B, Williams D, Swain F, et al. PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan. J Bone Miner Res. 2017;32:1421-1431 pubmed publisher
Bellini G, Torella M, Manzo I, Tortora C, Luongo L, Punzo F, et al. PKC?II-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity. Pharmacol Res. 2017;115:267-274 pubmed publisher
Savage J, Pulsipher A, Rao N, Kennedy T, Prestwich G, Ryan M, et al. A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis. PLoS ONE. 2016;11:e0157310 pubmed publisher
Zhu K, Yi J, Xiao Y, Lai Y, Song P, Zheng W, et al. Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy. J Biol Chem. 2015;290:8081-94 pubmed publisher
Kalbasi Anaraki P, Patecki M, Tkachuk S, Kiyan Y, Haller H, Dumler I. Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-ÎºB pathway in osteoclasts. J Bone Miner Res. 2015;30:379-88 pubmed publisher
Zheng Y, Chow S, Boernert K, Basel D, Mikuscheva A, Kim S, et al. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J Bone Miner Res. 2014;29:1938-49 pubmed publisher
Yeon J, Kim K, Choi S, Moon S, Park Y, Ryu B, et al. Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLC?-independent Ca2+ oscillation. PLoS ONE. 2014;9:e88974 pubmed publisher
Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, et al. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS ONE. 2013;8:e82453 pubmed publisher
Chen C, Cheng P, Xie H, Zhou H, Wu X, Liao E, et al. MiR-503 regulates osteoclastogenesis via targeting RANK. J Bone Miner Res. 2014;29:338-47 pubmed publisher
He W, Mazumder A, Wilder T, Cronstein B. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J. 2013;27:3446-54 pubmed publisher
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher
Søe K, Delaisse J. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res. 2010;25:2184-92 pubmed publisher
Boissy P, Andersen T, Lund T, Kupisiewicz K, Plesner T, Delaisse J. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res. 2008;32:1661-8 pubmed publisher
Colucci S, Brunetti G, Cantatore F, Oranger A, Mori G, Quarta L, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007;212:47-55 pubmed
Tang C, Hsu T, Lin W, Lai M, Yang R, Hsieh S, et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem. 2007;282:2346-54 pubmed
Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux N, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol. 2006;169:987-98 pubmed
Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol. 2003;163:2021-31 pubmed

product information

brand :

R&D Systems

master code :

390-TN

SKU :

390-TN-010

product name :

Recombinant Human TRANCE/RANK L/TNFSF11 Protein

description :

The Recombinant Human TRANCE/RANK L/TNFSF11 Protein from R&D Systems is derived from NS0. The Recombinant Human TRANCE/RANK L/TNFSF11 Protein has been validated for the following applications: Bioactivity.

target :

TRANCE/TNFSF11/RANK L

category :

Proteins and Enzymes

unit size :

10 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in MOPS and NaCl with BSA as a carrier protein.

conjugate :

Unconjugated

purity :

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

35 kDa, reducing conditions

theoretical molecular weight :

23 kDa

gene symbol :

TNFSF11

details of functionality :

Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 1.5-7.5 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050 ).

endotoxin note :

<0.10 EU per 1 µg of the protein by the LAL method.

catalog number base :

390-TN

accessionNumbers :

AAC51762

applications :

Bioactivity

source :

Mouse myeloma cell line, NS0-derived human TRANCE/TNFSF11/RANK L protein MHHHHHHHHHH GGGSGGGSGGGS IEGR Human TRANCE (Gly64-Asp245) Accession # AAC51762 N-terminus C-terminus

extended description :

A New rh TRANCE is Now Available! The new protein has no tag!

2020 USD :

329

2021 USD :

329 USD

product details :

A New rh TRANCE is Now Available! The new protein has no tag!

alt names :

CD254, CD254 antigen, ODF, OPGL, OPGLOPTB2, Osteoclast differentiation factor, Osteoprotegerin ligand, RANK L, RANKL, RANKLreceptor activator of nuclear factor kappa B ligand, Receptor activator of nuclear factor kappa-B ligand, sOdf, TNF-related activation-induced cytokine, TNFSF11, TRANCEODFhRANKL2, tumor necrosis factor (ligand) superfamily, member 11, tumor necrosis factor ligand superfamily member 11

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.